Aspartoacylase suppresses prostate cancer progres-sion by blocking LYN activation

Hong Weng; Kang-Ping Xiong; Wang Wang; Kai-Yu Qian; Shuai Yuan; Gang Wang; Fang Yu; Jun Luo; Meng-Xin Lu; Zhong-Hua Yang; Tao Liu; Xing Huang; Hang Zheng; Xing-Huan Wang

doi:10.1186/s40779-023-00460-0

您当前的位置：

首页 >

文章列表页 >

Aspartoacylase suppresses prostate cancer progres-sion by blocking LYN activation

RESEARCH | 更新时间：2025-12-13

- Aspartoacylase suppresses prostate cancer progres-sion by blocking LYN activation
- Aspartoacylase suppresses prostate cancer progres-sion by blocking LYN activation
- “武汉大学中南医院的一项研究报道了癌症前列腺研究的突破，该研究确定天冬氨酰酶（ASPA）是一种新型的疾病进展抑制剂。这项研究涉及先进的转录组学方法和全面的体外和体内测定，发现ASPA表达降低与患者预后不良有关，其活性抑制癌症细胞增殖和转移。该研究揭示了ASPA与LYN的直接相互作用，抑制其磷酸化和下游信号传导，为前列腺癌症的治疗提供了新的方向。”
- Hong Weng ，Kang-Ping Xiong ，Wang Wang ，Kai-Yu Qian ，Shuai Yuan ，Gang Wang ，Fang Yu ，Jun Luo ，Meng-Xin Lu ，Zhong-Hua Yang ，Tao Liu ，Xing Huang ，Hang Zheng ，Xing-Huan Wang
- MMR 2024年11卷第2期页码：180-205
- 作者机构：
  1.Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China
  2.Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, China
  3.Department of Biological Repositories, Zhongnan Hospital of Wuhan University, Wuhan 430071, China
  4.Hubei Key Laboratory of Tumor Biological Behaviors, Wuhan 430071, China
  5.Department of Pathology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China
  6.Center for Pathology and Molecular Diagnostics, Wuhan University, Wuhan 430071, China
  7.Wuhan Research Center for Infectious Diseases and Cancer, Chinese Academy of Medical Sciences, Wuhan 430071, China
- 作者简介：
  *wangxinghuan@whu.edu.cn
- 基金信息：
  the Science and Technology Department of Hubei Province Key Project(YYXKNL2022001);the Non-Profit Central Research Institute Fund of Chinese Academy of Medical Sciences(2020-PT320-004);the Hubei Provincial Natural Science Foundation(2021CFB453);the Science, Technology and Innovation Seed Fund of Zhongnan Hospital of Wuhan University(CXPY2020031);the Climbing Program for Medical Talents of Zhongnan Hospital of Wuhan University(PDJH202206;PDJH202208);The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript
- DOI： 10.1186/s40779-023-00460-0
  中图分类号：
- 稿件说明：
移动端阅览
DOI：
DOI：

AI导读
HTML全文
图( 9 ) 表( 4 )
参考文献
出版信息
数据统计

86

浏览量

45

下载量

0

CSCD

文章被引用时，请邮件提醒。

提交

工具集

BibTeX下载
Endnote下载
RefMan 下载
NoteExpress下载
NoteFirst下载

关联资源

Global burden of benign prostatic hyperplasia, urinary tract infections, urolithiasis, bladder cancer, kidney cancer, and prostate cancer from 1990 to 2021

ADP-dependent glucokinase: the ancient, archaeal key to prostate cancer

The implications of single-cell RNA-seq analysis in prostate cancer: unraveling tumor heterogeneity, therapeutic implications and pathways towards personalized therapy

Frostbite: diagnosis, treatment, prognosis, and future directions

Aspartoacylase suppresses prostate cancer progres-sion by blocking LYN activation

Aspartoacylase suppresses prostate cancer progres-sion by blocking LYN activation

DOI： 10.1186/s40779-023-00460-0

AI导读

HTML全文

图( 9 ) 表( 4 )

参考文献

出版信息

数据统计

摘要

Abstract

关键词

Keywords

references